Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVaxil Bio Ltd

Vaxil Bio Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.11 CAD 0.01 ( 10.00%)
Last update at 2026-11-04T14:30:00Z
VOLUME
1121
Market Cap
0.56M

Momentum Score

…

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.11
Low
0.11
High
52 Week Price Range
0.01
Low
0.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Vaxil Bio Ltd is a clinical-stage biotechnology firm developing immunotherapies and diagnostic products using a proprietary platform that targets tumor-associated antigens; its lead program concentrates on a MUC1-targeting therapeutic vaccine candidate evaluated in clinical studies. Long-term growth may be supported by positive clinical progression, regulatory approvals, licensing or partnerships and expansion into additional cancer indications, and investors may find exposure to a focused immuno-oncology pipeline attractive.

The most important risks are clinical and regulatory failure, limited or no product revenues, and significant financing and dilution risk typical of small-cap biotechs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.10
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-13.38%
Net Debt
-0.94M
ROCE
-27.37%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -0.18M -0.00M -0.58M -0.99M -1.36M
Net income -0.18M -0.00M -0.58M -0.99M -1.37M
Selling general administrative 0.18M 0.00M 0.24M 0.43M 0.72M
Selling and marketing expenses - 0.00M - - -
Gross profit - - -0.00M -0.03M -0.06M
Reconciled depreciation - 0.00M 0.00M 0.03M 0.06M
Ebit - -0.17M -0.58M -0.99M -1.35M
Ebitda - -0.00M -0.58M -0.96M -1.29M
Depreciation and amortization - 0.17M 0.00M 0.03M 0.06M
Operating income -0.20M -0.00M -0.58M -0.99M -1.35M
Other operating expenses - 0.00M 0.58M 0.99M 1.35M
Interest expense - - - 0.00M 0.01M
Interest income 0.02M - - - -
Net interest income 0.02M - - 0.00M -0.01M
Income tax expense - - - - 0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 0.20M 0.00M 0.58M 0.99M 1.35M
Cost of revenue - - 0.00M 0.03M 0.06M
Total other income expense net - 0.01M - - -0.01M
Net income from continuing ops -0.18M -0.25M -0.58M -0.99M -1.36M
Net income applicable to common shares - - - -0.99M -1.36M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 0.73M 0.98M 1.54M 2.29M 1.66M
Other current assets - 0.00M - - -
Total liab 0.02M 0.09M 0.41M 0.58M 0.86M
Total stockholder equity 0.72M 0.89M 1.14M 1.70M 0.80M
Other current liab - 0.08M - - 0.26M
Common stock - 16.07M 16.07M 16.07M 13.86M
Capital stock 16.07M 16.07M 16.07M 16.07M 13.86M
Retained earnings -19.54M -19.36M -19.10M -18.52M -17.53M
Cash 0.45M 0.94M 1.51M 2.24M 1.51M
Total current liabilities 0.02M 0.09M 0.41M 0.58M 0.86M
Net debt - -0.94M - - -
Other stockholder equity - 0.00M - 0.28M 0.69M
Property plant equipment - - - 0.00M 0.03M
Total current assets 0.73M 0.98M 1.54M 2.28M 1.63M
Net tangible assets - - - 1.70M 0.80M
Net receivables - 0.02M - 0.04M 0.03M
Inventory - 0.02M - - -
Accounts payable - 0.00M - 0.58M 0.57M
Accumulated other comprehensive income - 4.17M - - -
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.03M
Capital lease obligations - - - 0.00M 0.01M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.25M - - - -
Change to liabilities - - 0.00M -0.28M -0.03M
Net borrowings - - - -0.01M -0.02M
Total cash from financing activities - - 0.04M 1.81M 2.56M
Change to operating activities - - - - 0.16M
Net income -0.18M -0.25M -0.58M -0.99M -1.36M
Change in cash -0.49M -0.57M -0.73M 0.73M 1.43M
Begin period cash flow 0.94M 1.51M 2.24M 1.51M 0.08M
End period cash flow 0.45M 0.94M 1.51M 2.24M 1.51M
Total cash from operating activities -0.24M -0.56M -0.73M -1.08M -1.10M
Issuance of capital stock - - - 0.00M 0.76M
Depreciation - 0.00M 0.00M 0.03M 0.06M
Change to inventory - - - 0.28M -
Change to account receivables 0.02M -0.01M 0.01M 0.08M -0.10M
Other cashflows from financing activities - - - 0.00M 1.86M
Change to netincome - - - 0.07M 0.16M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.05M -0.33M -0.17M -0.19M 0.04M
Stock based compensation 0.01M 0.02M 0.02M 0.07M 0.15M
Other non cash items -0.02M -0.00M 0.01M 0.04M 0.01M
Free cash flow -0.24M -0.56M -0.73M -1.08M -1.10M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
VXL
Vaxil Bio Ltd		 0.01
10.00%		 0.11 - - - 0.57 -1.84
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 -
NRX
NurExone Biologic Inc.		 -0.01
2.00%		 0.49 - 6.90 - 15.26 -7.24
MIR
MedMira Inc		 -
-%		 0.06 - - 223.37 - -80.03
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17 -58.16

Profile*

Vaxil Bio Ltd

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada.

559 Briar Hill Avenue, Toronto, ON, Canada, M5N 1N1

647-558-5564

https://vaxil-bio.com

Name Title Year Born
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A., MBA Chairman & CFO 1973
Dr. Yuval Avnir Ph.D. Head of R&D & CEO NA
Dr. Riva Kovjazin M.D. Sr. Scientist & Member of Scientific Advisory Board NA
Mr. David Goren CEO & Chairman NA
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A. CFO & Director 1973
Dr. Riva Kovjazin M.D. Senior Scientist & Member of Scientific Advisory Board NA
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A. CEO & Chairman 1973
Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA Chief Financial Officer 1952

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.34
+14.45%
OMG
CAD 1.70
+13.76%
ARTG
CAD 39.54
+12.59%
DSV
CAD 10.83
+12.58%
TLRY
CAD 4.17
+12.10%
DRUG
CAD 25.95
-30.02%
HUT
CAD 69.16
-22.20%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.70
-15.62%
VET
CAD 15.04
-13.31%

Equity Sectors*

  • Basic Materials

    +4.80%

  • Communication Services

    +2.78%

  • Consumer Cyclical

    +2.82%

  • Consumer Defensive

    +0.74%

  • Energy

    -4.92%

  • Financial Services

    +2.47%

  • Healthcare

    -0.30%

  • Industrials

    -0.38%

  • Real Estate

    +1.75%

  • Technology

    +0.82%

  • Utilities

    +1.29%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…